In this eBook learn how MolecularMD is harnessing the company's unique capabilities to address diagnostic needs within immuno-oncology.
In this eBook, sponsored by Qiagen, we explore the opportunities and challenges of precision oncology and how molecular profiling is fundamental not only to inform on tumor diagnosis and prognosis, but also to drive therapeutic decisions in routine clinical care.
Single-Cell Functional Proteomics Accelerates Immunotherapy Development Opportunities from Pre-Clinical to Clinical Stages
IsoPlexis’ next generation systems provide actionable potency, safety, and patient difference metrics by detecting highly potent single cell functional subsets for the first time.
Download this eBook to learn how MolecularMD helped usher in a new era of CML treatment now prescribed by progressive clinicians.
Oxford Nanopore’s DNA/RNA sequencing technology delivers ultra-long reads (up to 2 Mb), enabling rapid and comprehensive analysis of variants. With devices scalable from portable to benchtop, nanopore sequencing offers a cost-effective solution to the challenges faced by traditional sequencing platforms.
Takeda has taken great strides in incorporating a patient-centric approach to drug development through the use of minimally invasive and less frequent testing procedures while maintaining the power and rigor of the clinical trial.
2015 was a phenomenal year full of new developments for the structures and mechanisms of CRISPR systems.
Codevelopment is an intermittent and uncertain process. Adopting an agnostic approach to the challenges associated with platform and method selection provide added degrees of freedom for strategic development and selection of the most appropriate clinical trial assay.
The challenges of incorporating NGS into clinical trials is being addressed through the adoption of robust technology solutions.
RNA and sequencing technologies have the potential to unlock the mystery of our every dynamic transcriptome.
12Page 1 of 2